Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Rubin Insider Profile
4 Followers
Paul Rubin, Sr. VP Clinical Dev. & CMO at Xoma, holds 145.17K shares in Xoma (Ticker: XOMA), holds ― shares in Viridian Therapeutics (Ticker: VRDN), holds 6.67K shares in Cornerstone Therapeutics Inc (Ticker: ~CRTX).
Paul Rubin has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Paul Rubin holds in companies
Most Profitable Insider Trade
The most profitable trade made by Paul Rubin
Paul Rubin's Trading History
Xoma
Mar 22, 2016
Sr. VP Clinical Dev. & CMO
Uninformative Sell
18.87K
$3.51M
Viridian Therapeutics
―
EVP, Research & Development
―
―
Cornerstone Therapeutics Inc
―
―
―
―
List of latest transactions for each holding click on a transaction to see Paul Rubin's performance on stock
You May Also Like
Paul Rubin insider profile FAQ
What is the percentage of profitable transactions made by Paul Rubin?
The percentage of profitable transactions made by Paul Rubin is ―.
What is the average return per transaction made by Paul Rubin?
The average return per transaction made by Paul Rubin is ―.
What stocks does Paul Rubin hold?
Paul Rubin holds: XOMA, VRDN, ~CRTX stocks.
What was Paul Rubin’s latest transaction?
Paul Rubin latest transaction was an Uninformative Sell of $18.87K.
What was Paul Rubin's most profitable transaction?
Paul Rubin’s most profitable transaction was an Informative Sell of XOMA stock on May 15, 2014. The return on the trade was 6.90%.
What is Paul Rubin's role in Xoma?
Paul Rubin's role in Xoma is Sr. VP Clinical Dev. & CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.